FDA Backs Proposed Stem Cell Trial for Treatment-Resistant Crohn’s Disease
StemSmart Crohn’s disease clinical trial gets positive FDA pre-IND feedback on 6 of 7 questions; a viral safety issue remains. Not a marketing approval.
StemSmart Crohn’s disease clinical trial gets positive FDA pre-IND feedback on 6 of 7 questions; a viral safety issue remains. Not a marketing approval.
Early data say 18 of 21 heart failure patients were treated at home with Lasix ONYU. What hospital leaders can and cannot conclude from a single-arm study.
Castle Biosciences says TissueCypher changed Barrett’s management for 96% of cohort patients. Where the test fits in surveillance and what is unproven.
Envoy Medical has filed 2 of 4 FDA modules for its investigational Acclaim implant. A status board of what is done, pending and still undisclosed.
Sun Pharma will raise up to ₹10,000 crore via NCDs, down from ₹15,000 crore, as Gautam Doshi quits. NCD terms explained, ratings and open questions.
Tortugas reports obuprazine beat placebo at all doses in a 363-patient Phase 2b. Five claims checked against the evidence, plus what is still missing.
Judges asked why India’s 30% cancer drug margin cap should not cover other medicines. What changes for makers, chemists, hospitals and patients.
Stryker commits about $400M to CMR Surgical, gains US Versius sales rights and a buy-out option. Answers on terms, risks and what is still undisclosed.
Philips Lumify ultrasound FDA safety alert: four deaths and eight serious injuries reported over two faults. What the FDA said and what users should do.